Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | GLP1R | P43220 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14349216 | 0.98 | P2RY12 (0.39) | P2RY12POLBGRM4TRPV1CHRM4 | |
| SCHEMBL15599194 | 0.86 | CHRNB2 (0.47) | — | |
| SCHEMBL12891545 | 0.86 | GRM4 (0.41) | P2RY12POLBGRM4SMN1; SMN2CNR2 | |
| SCHEMBL14349670 | 0.81 | DHODH (0.40) | SMN1; SMN2LMNAMAPTTP53HPGD | |
| SCHEMBL17693905 | 0.80 | ALDH1A1 (0.38) | TRPV1SMN1; SMN2TP53HTT | |
| SCHEMBL14349215 | 0.80 | DHODH (0.41) | SMN1; SMN2CNR2MAPTTP53HPGD | |
| SCHEMBL16248221 | 0.80 | CRHR1 (0.43) | LMNAMEN1KMT2AMAPTHTT | |
| SCHEMBL21470275 | 0.79 | LMNA (0.47) | POLBSMN1; SMN2LMNAMAPTHPGD | |
| SCHEMBL16248215 | 0.79 | OPRK1 (0.45) | LMNAMAPTHTT | |
| SCHEMBL17696414 | 0.77 | POLB (0.43) | POLBGRM4CHRM4GLP1RSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155330-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2018-06-07 | — | — | US | disclosed |
| US-20180155330-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2018-06-07 | — | — | US | disclosed |
| US-9873687-B2 | N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors | ACTIVE BIOTECH AB (SE) | 2018-01-23 | — | — | US | disclosed |
| US-9873687-B2 | N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors | ACTIVE BIOTECH AB (SE) | 2018-01-23 | — | — | US | disclosed |
| US-9533987-B2 | Heterocyclic derivates | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2017-01-03 | — | — | US | disclosed |
| US-20160115158-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2016-04-28 | — | — | US | disclosed |
| US-20160108036-A1 | HETEROCYCLIC DERIVATES | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2016-04-21 | — | — | US | disclosed |
| EP-2925743-B1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2016-02-03 | — | — | EP | disclosed |
| WO-2014184234-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2014-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155330-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | S100A9, S100B, S100A10 | P2RY12 1030/4885POLB 4386/4885GRM4 1285/4885 |
| US-20160108036-A1 | HETEROCYCLIC DERIVATES | BDKRB1, KLKB1, BDKRB2 | P2RY12 3664/4885POLB 3416/4885GRM4 4230/4885 |
| US-20160115158-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | S100A9, S100A4, S100B | P2RY12 997/4885POLB 4800/4885GRM4 1326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.